Status:

COMPLETED

A Clinical Trial of a Gamified Attention Bias Modification Training in Anxious Youth

Lead Sponsor:

National Institutes of Health Clinical Center (CC)

Conditions:

Anxiety Disorders

Eligibility:

All Genders

8-17 years

Phase:

NA

Brief Summary

Background: Attention bias modification training (ABMT) and cognitive behavioral therapy (CBT) likely target different aspects of aberrant threat responses in anxiety disorders and may be combined to ...

Detailed Description

Background: Attention bias modification training (ABMT) and cognitive behavioral therapy (CBT) likely target different aspects of aberrant threat responses in anxiety disorders and may be combined to ...

Eligibility Criteria

Inclusion

  • INCLUSION CRITERIA:
  • ALL JUVENILE SUBJECTS WITH AN ANXIETY DISORDER:
  • Diagnosis: Current Diagnosis of Social Phobia, Separation Anxiety, Generalized Anxiety Disorder, or Panic Disorder (Based on K-SADS (juveniles))
  • Symptom Severity: Clinically significant, ongoing anxiety symptoms
  • Clinical Impairment: Clinically significant, ongoing distress or impairment from anxiety
  • Age: 8 - 17 (subjects who consent as 17- year-olds but turn 18 during the course of the study will be eligible to complete all procedures completed by other subjects who consent as 17- year- old but do not turn 18).
  • Consent: can give consent/assent (Parents will provide consent; minors will provide assent)
  • IQ: all subjects will have intelligence quotient (IQ) \> 70 (Assessment relies on WASI)
  • Language: all subjects will speak English
  • EXCLUSION CRITERIA:
  • Any serious medical condition or condition that interferes with participation
  • Pregnancy
  • Current use of any psychoactive substance; current suicidal ideation; current diagnosis of attention deficit hyperactivity disorder (ADHD) of sufficient severity to require pharmacotherapy.
  • Current diagnoses Tourette's Disorder, obsessive compulsive disorder (OCD), post-traumatic distress disorder, conduct disorder
  • Past or current history of mania, psychosis, or severe pervasive developmental disorder
  • Recent use of an selective serotonin reuptake inhibitor (SSRI); all subjects must have been free of any SSRI-use for at least one month (fluoxetine six months) and must not have been treated with an SSRI for their current depressive episode.
  • National Institute of Mental Health (NIMH) employees and staff and their immediate family members will be excluded from the study per NIMH policy

Exclusion

    Key Trial Info

    Start Date :

    November 1 2016

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    September 1 2023

    Estimated Enrollment :

    121 Patients enrolled

    Trial Details

    Trial ID

    NCT03283930

    Start Date

    November 1 2016

    End Date

    September 1 2023

    Last Update

    April 9 2024

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    NIH Clinical Center

    Bethesda, Maryland, United States, 20892